After topping the Street's expectations with its Q3 earnings, Cipla announced plans to launch two key drugs in FY26—the respiratory drug Advair and the oncology drug Abraxane. Umang Vohra ...

HYDERABAD/BENGALURU (Reuters) -Cipla, one of India's largest drugmakers by sales, reported a bigger-than-expected third-quarter profit on Tuesday helped by strong domestic demand, and said the U.S ...

Pharmaceutical giant Cipla on January 28 reported a consolidated net profit of Rs 1,571 crore for the quarter ended on December 31. This marks a 49 percent rise from the Rs 1,056 crore net profit ...

HYDERABAD/BENGALURU, Jan 28 (Reuters) - Cipla (CIPL.NS), opens new tab, one of India's largest drugmakers by sales, reported a bigger-than-expected third-quarter profit on Tuesday helped by strong ...

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

Shares traded at ₹358.05 on the NSE, down 2.09%. Cipla Ltd recorded its consolidated net profit for the quarter ended December 2024 at ₹1,574.59 crore as against ₹1,068.41 crore in the ...

Cipla: The pharma player has informed the exchanges that its manufacturing facility in Bengaluru's Virgonagar has received a Voluntary Action Indicated status from the USFDA. VA Tech Wabag ...

Cipla's stock is currently valued at Rs 1459.25, reflecting a daily change of -0.88%. The 3-day exponential moving average is Rs 1475.38. Cipla is currently priced at Rs 1463.10, indicating a decrease ...

Cipla's stock is priced at Rs 1473.75, showing an increase of 1.7% today, with a monthly return of 2.73%. Cipla's shares are currently priced at Rs 1477.55, reflecting a daily increase of 1.96%. The ...

Cipla Q3 results review: The shares of the third largest pharmaceutical firm Cipla rose 2.44 per cent at Rs 1,454.20 a piece on the BSE intraday after the company delivered a solid quarterly earnings ...